Savoy's founder discovers Thymidine Kinase 1 (TK1) is found in significant quantities on the surface of cancer cells. Conventional wisdom and science previously held that TK1 was found only inside of the nucleus of cells where it acts as an enzyme in the creation of the DNA precursor thymidine monophosphate. Were this true it would have made it unusable as a target for antibody-based therapy.
2004-2009: TESTING THE DISCOVERY
Savoy Pharmaceuticals™ is founded and begins testing to determine the viability of TK1 as a tumor marker. Savoy performed several experiments including in-vitro florescence microscopy and flow cytometry to demonstrate the ability of the anti-TK1 antibody to differentially bind to and destroy cancer cells. The results indicated that Savoy's antibody detects TK1 on the surface of cancer cells, and does not show any TK1 on the surface of normal lymphocytes or fibroblasts.
2009-2011: DEVELOPING THE THERAPY
Savoy Pharmaceuticals™ designs a human monoclonal antibody targeting TK1 and destroying the cancerous cells while leaving healthy cells unharmed. Savoy is granted patents to this discovery.
2011: RECENT RESEARCH
Validated this discovery on HCV and HIV infected cells and resultant HCV-associated liver cancer.
2014: CLINICAL TRIALS
Savoy Pharmaceuticals™ prepares to submit an IND to the FDA to begin clinical trials for this cancer therapy with the first target being liver cancer